Synergy CHC (SNYR) Competitors $2.69 +0.32 (+13.50%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNYR vs. VTVT, ADAG, CLNN, IFRX, IMUX, ASRT, IMMX, UNCY, RPTX, and VXRTShould you be buying Synergy CHC stock or one of its competitors? The main competitors of Synergy CHC include vTv Therapeutics (VTVT), Adagene (ADAG), Clene (CLNN), InflaRx (IFRX), Immunic (IMUX), Assertio (ASRT), Immix Biopharma (IMMX), Unicycive Therapeutics (UNCY), Repare Therapeutics (RPTX), and Vaxart (VXRT). These companies are all part of the "pharmaceutical products" industry. Synergy CHC vs. Its Competitors vTv Therapeutics Adagene Clene InflaRx Immunic Assertio Immix Biopharma Unicycive Therapeutics Repare Therapeutics Vaxart Synergy CHC (NASDAQ:SNYR) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings. Does the media prefer SNYR or VTVT? In the previous week, vTv Therapeutics had 2 more articles in the media than Synergy CHC. MarketBeat recorded 3 mentions for vTv Therapeutics and 1 mentions for Synergy CHC. Synergy CHC's average media sentiment score of 0.73 beat vTv Therapeutics' score of 0.42 indicating that Synergy CHC is being referred to more favorably in the media. Company Overall Sentiment Synergy CHC Positive vTv Therapeutics Neutral Do analysts rate SNYR or VTVT? Synergy CHC currently has a consensus price target of $10.00, indicating a potential upside of 271.75%. vTv Therapeutics has a consensus price target of $35.50, indicating a potential upside of 71.84%. Given Synergy CHC's stronger consensus rating and higher possible upside, research analysts plainly believe Synergy CHC is more favorable than vTv Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synergy CHC 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00vTv Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Do institutionals & insiders have more ownership in SNYR or VTVT? 17.5% of vTv Therapeutics shares are held by institutional investors. 56.6% of Synergy CHC shares are held by company insiders. Comparatively, 4.2% of vTv Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is SNYR or VTVT more profitable? Synergy CHC has a net margin of 10.02% compared to vTv Therapeutics' net margin of 0.00%. Synergy CHC's return on equity of -18.56% beat vTv Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Synergy CHC10.02% -18.56% 20.28% vTv Therapeutics N/A -179.75%-55.91% Which has better earnings and valuation, SNYR or VTVT? Synergy CHC has higher revenue and earnings than vTv Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than Synergy CHC, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynergy CHC$34.83M0.73$2.12M$0.387.08vTv Therapeutics$1.02M79.80-$18.46M-$3.12-6.62 SummarySynergy CHC beats vTv Therapeutics on 12 of the 16 factors compared between the two stocks. Get Synergy CHC News Delivered to You Automatically Sign up to receive the latest news and ratings for SNYR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNYR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNYR vs. The Competition Export to ExcelMetricSynergy CHCCONS PD IndustryStaples SectorNASDAQ ExchangeMarket Cap$25.39M$33.18B$16.12B$10.54BDividend YieldN/A2.74%3.24%4.78%P/E Ratio7.0836.8717.6727.10Price / Sales0.732.0047.45130.49Price / Cash8.2315.5814.5362.13Price / Book-1.418.077.226.58Net Income$2.12M$1.23B$678.09M$276.75M7 Day Performance20.63%0.39%1.87%0.92%1 Month Performance19.56%-6.72%-0.05%4.20%1 Year PerformanceN/A14.57%-0.65%37.86% Synergy CHC Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNYRSynergy CHC4.2343 of 5 stars$2.69+13.5%$10.00+271.7%N/A$25.39M$34.83M7.0840Short Interest ↓Gap UpVTVTvTv Therapeutics1.5037 of 5 stars$22.10+1.3%$35.50+60.6%+49.2%$87.07M$1.02M-7.089Analyst ForecastGap DownADAGAdagene2.3448 of 5 stars$1.84-3.7%$7.00+280.4%-25.5%$86.72M$100K0.00260Short Interest ↑Gap UpCLNNClene3.8719 of 5 stars$8.59+4.1%$32.60+279.5%+45.5%$86.50M$340K-2.28100Analyst ForecastIFRXInflaRx2.9472 of 5 stars$1.28+2.4%$6.20+384.4%-17.9%$85.93M$180K-1.6060News CoveragePositive NewsAnalyst ForecastIMUXImmunic2.2422 of 5 stars$0.85-5.5%$9.50+1,024.1%-47.0%$83.37MN/A-0.9070ASRTAssertio2.8214 of 5 stars$0.86+2.5%$2.38+175.2%-27.1%$83.05M$124.96M-1.9220Positive NewsIMMXImmix Biopharma3.3254 of 5 stars$2.48-0.8%$8.00+222.6%+87.5%$81.94MN/A-3.229Gap DownUNCYUnicycive Therapeutics3.0922 of 5 stars$4.56+1.6%$57.00+1,150.0%+20.7%$80.53M$680K-1.119RPTXRepare Therapeutics3.1196 of 5 stars$1.87+2.7%$4.50+140.6%-45.6%$80.34M$53.48M-0.72180VXRTVaxart1.924 of 5 stars$0.34+1.3%$2.00+482.2%-56.4%$78.64M$47.40M-1.27120 Related Companies and Tools Related Companies vTv Therapeutics Competitors Adagene Competitors Clene Competitors InflaRx Competitors Immunic Competitors Assertio Competitors Immix Biopharma Competitors Unicycive Therapeutics Competitors Repare Therapeutics Competitors Vaxart Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNYR) was last updated on 10/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synergy CHC Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synergy CHC With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
